115. Hereditary periodic paralysis
1 clinical trial, 2 drugs (DrugBank: 2 drugs), 13 drug target genes, 7 drug target pathways
Searched query = "Hereditary periodic paralysis", "Hereditary Hypokalemic Periodic Paralysis", "Andersen-Tawil syndrome", "Hereditary Hyperkalemic Periodic Paralysis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00839501 (ClinicalTrials.gov) | December 2008 | 5/2/2009 | Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome | Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome | Andersen-Tawil Syndrome | Dietary Supplement: Potassium;Drug: Acetazolamide | University of Rochester | Office of Rare Diseases (ORD);Rare Diseases Clinical Research Network;National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | 10 Years | N/A | Both | 3 | Phase 1 | United States;United Kingdom |